Edward P Feener Selected Research

Retinaldehyde (Retinal)

1/2019	Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy.
1/2019	Retinal proteome associated with bradykinin-induced edema.
10/2015	Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema.
9/2015	Thrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an Inflammatory Standpoint.
3/2013	Plasma kallikrein-kinin system and diabetic retinopathy.
2/2013	Intraocular hemorrhage causes retinal vascular dysfunction via plasma kallikrein.
5/2011	Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats.
8/2010	Plasma kallikrein and diabetic macular edema.
2/2009	Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability.
2/2007	Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edward P Feener Research Topics

Disease

12	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2019 - 01/2002
7	Hemorrhage 01/2022 - 02/2007
7	Macular Edema 12/2019 - 03/2006
6	Hereditary Angioedemas 11/2023 - 01/2022
6	Edema (Dropsy) 01/2023 - 12/2010
5	Hypertension (High Blood Pressure) 01/2022 - 01/2002
4	Thrombosis (Thrombus) 11/2021 - 04/2016
4	Hyperglycemia 01/2019 - 02/2011
4	Inflammation (Inflammations) 01/2016 - 02/2007
4	Insulin Resistance 06/2014 - 02/2005
3	Retinal Hemorrhage 01/2017 - 02/2007
3	Retinal Neovascularization 01/2016 - 03/2006
3	Leukostasis 02/2013 - 03/2006
2	Angioedema 01/2023 - 01/2017
2	Stroke (Strokes) 01/2022 - 01/2017
2	Cerebral Hemorrhage 01/2022 - 01/2017
2	Hematoma 01/2017 - 02/2011
2	Papilledema 01/2016 - 02/2007
2	Ischemia 09/2015 - 10/2006
2	Type 2 Diabetes Mellitus (MODY) 06/2014 - 02/2005
2	Obesity 06/2014 - 04/2008
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2012 - 04/2005
1	Paresthesia (Dysesthesia) 03/2024
1	COVID-19 03/2024
1	Anaphylaxis (Anaphylactic Shock) 03/2024
1	Hypersensitivity (Allergy) 03/2024
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2022
1	Pain (Aches) 01/2022
1	Neoplasms (Cancer) 11/2021
1	Low Vision (Subnormal Vision) 12/2019
1	Mitochondrial Diseases (Mitochondrial Disease) 06/2017
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2017
1	Wounds and Injuries (Trauma) 01/2017
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2017
1	Thrombotic Stroke 01/2017
1	Carotid Artery Thrombosis 04/2016
1	Venous Thrombosis (Deep-Vein Thrombosis) 04/2016
1	Retinal Perforations 10/2015

Drug/Important Bio-Agent (IBA)

18	Plasma KallikreinIBA 11/2023 - 02/2009
12	Retinaldehyde (Retinal)IBA 01/2019 - 03/2006
7	PrekallikreinIBA 01/2022 - 02/2007
6	BradykininIBA 01/2022 - 02/2009
6	Proteins (Proteins, Gene)FDA Link 01/2017 - 02/2007
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 01/2002
5	Angiotensin IIIBA 08/2013 - 04/2005
4	Factor XII (Hageman Factor)IBA 11/2021 - 08/2010
4	ProteomeIBA 01/2019 - 02/2007
3	KininsIBA 11/2023 - 03/2013
3	Kininogens (Kininogen)IBA 11/2023 - 08/2010
3	sebetralstatIBA 11/2023 - 01/2022
3	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 09/2007
3	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2017 - 02/2011
2	Messenger RNA (mRNA)IBA 03/2024 - 06/2017
2	Lysine (L-Lysine)FDA Link 11/2023 - 01/2022
2	Enzyme Precursors (Zymogens)IBA 01/2023 - 04/2016
2	AcidsIBA 01/2022 - 02/2009
2	High-Molecular-Weight Kininogen (Kininogen, High Molecular Weight)IBA 01/2022 - 04/2016
2	Kallikreins (Kallikrein)IBA 04/2016 - 02/2007
2	Oxygen (Dioxygen)IBA 01/2016 - 03/2006
2	Tyrosine (L-Tyrosine)FDA Link 08/2013 - 02/2005
2	Protein Kinase CIBA 08/2013 - 04/2005
2	Insulin (Novolin)FDA Link 08/2013 - 09/2007
2	Serine (L-Serine)FDA Link 08/2013 - 09/2007
2	candesartanIBA 02/2009 - 03/2006
1	mRNA VaccinesIBA 03/2024
1	BNT162 VaccineIBA 03/2024
1	VaccinesIBA 03/2024
1	Biomarkers (Surrogate Marker)IBA 03/2024
1	CarrageenanIBA 01/2023
1	Evans Blue (Blue, Evans)FDA Link 01/2023
1	Captopril (Capoten)FDA LinkGeneric 01/2023
1	protein kinase modulatorIBA 01/2022
1	Hormones (Hormone)IBA 01/2022
1	Atrial Natriuretic Factor (ANF)IBA 01/2022
1	SaltsIBA 01/2022
1	Antisense OligonucleotidesIBA 01/2022
1	PlasminogenIBA 01/2022
1	PolyphosphatesIBA 11/2021
1	Thromboplastin (Tissue Factor)IBA 11/2021
1	CytokinesIBA 01/2019
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 01/2019
1	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 01/2019
1	ML-265IBA 06/2017
1	Pyruvate KinaseIBA 06/2017
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2017
1	Hemostatics (Antihemorrhagics)IBA 01/2017
1	Therapeutic UsesIBA 01/2017
1	Rose BengalIBA 04/2016
1	Peptide Hydrolases (Proteases)FDA Link 04/2016
1	EnzymesIBA 04/2016
1	Factor XIIa (Coagulation Factor XIIa)IBA 04/2016
1	Serine Proteases (Serine Protease)IBA 01/2016
1	Blood Coagulation Factors (Coagulation Factor)IBA 09/2015
1	Thrombin FDA Link 09/2015
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 09/2015
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2013

Therapy/Procedure

4	Therapeutics 11/2023 - 01/2012
4	Intravitreal Injections 12/2019 - 02/2009
3	Thrombolytic Therapy 01/2022 - 01/2017
1	Glycemic Control 01/2019